News & Articles

Study to Establish Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Olanzapine Delivered via Precision Olfactory Delivery (POD®) Device SEATTLE, August 29, 2018 — Impel NeuroPharma, a Seattle-based, privately-held biopharmaceutical company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced the first subject has been dosed in a...

August 27, 2018 Abstract Objectives: Primary: Compare the safety and tolerability of intranasal INP103 to placebo in patients with PD during an OFF episode. Secondary: Characterize the PK of single ascending doses of INP103; Explore the effect of single ascending doses of INP103 versus placebo on motor function and PK/pharmacodynamic relationship of...

August 24, 2008 -- In 2008, Dr. John Hoekman was a Ph.D. student in pharmaceutics who had just won a UW business plan competition and was granted $25,000 to start his company. It’s been ten years since the incorporation of Impel in 2008, and we’ve grown from just three devoted dreamers to...

Safety and Tolerability of POD-DHE (STOP-301) Trial to Explore Safety and Tolerability of Long-Term Intermittent Use of Intranasal Dihydroergotamine Mesylate Delivered via Precision Olfactory Delivery (POD®) Device STOP-301 Trial Recruiting More Quickly Than Expected, Company On-Track With 2019 NDA Filing SEATTLE, August 22, 2018 — Impel NeuroPharma, a Seattle-based, privately-held biopharmaceutical company...

The International Association of Parkinsonism and Related Disorders world congress will be held in Lyon, France on 19-22 August. Dr. Stephen Shrewsbury, CMO will be presenting a poster on A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Safety and Pharmacokinetic/Pharmacodynamic (PK/PDyn) Study of INP103 (POD® L dopa) Administered in the...

Impel's Clinical Operations team will be attending the annual summer networking event of the Pacific Northwest Association of Clinical Research Professionals (ACRP). The event will be held Tuesday, August 7 at 5:30 - 7:30 PM at Chandler's Crabhouse on Lake Union.  For more information, visit the event webpage here....

SEATTLE, July 16, 2018 — Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced that Lynn C. Gold, Ph.D., has joined the Company as the Senior Vice President of Regulatory Affairs. In this capacity, Gold has extensive oversight of regulatory...

SEATTLE, June 26, 2018 — Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced new data from the Company’s investigational drug INP104 for acute migraine will be presented at the American Headache Society’s 60th Annual Meeting, June 28...